Drug Discovery

Durvalumab and Pabolizumab for lung cancer treatment

Durvalumab and Pabolizumab for lung cancer treatment

Small cell lung cancer (SCLC) is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer cases. Among them, about three-quarters of patients with small […]

New drug for alopecia areata

New drug for alopecia areata

Concert Pharma recently released the results of its phase II clinical trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia areata, an […]

“Opportunities and Challenges” in the development of the HDACs drugs for cancers

“Opportunities and Challenges” in the development of the HDACs drugs for cancers

Despite the popularity in the development of histone deacelytase (HDAC) inhibitors, the indications of the five already approved HDAC inhibitor drugs on the market are limited to peripheral T-cell lymphoma […]

PD-L1

PD-L1

Introduction Programmed death-ligand 1 (PD-L1) is a protein that is highly expressed on the surface of many cancer cells. As PD-L1’s receptor, PD-1 belongs to the immunoglobulin superfamily and can […]

Osimertinib was approved for first-line treatment

Osimertinib was approved for first-line treatment

The third-generation EGFR inhibitor, Osimertinib (Tagrisso, AZD9291), was approved by the Chinese Food and Drug Administration (NMPA) recently for first-line treatment of patients with EGFR mutation-positive advanced or metastatic non-small cell lung […]

PD-1

PD-1

Introduction Programmed cell death 1 (PD-1) is a costimulatory molecule that belongs to the CD28/CTLA-4 family. PD-1 recruits and activates an activation signaling pathway such as protein tyrosine phosphatase by binding […]

JAK1 inhibitor Rinvoq (upadacitinib) approved by the FDA in the United States

  Upadacitinib tartrate, a small-molecule selective inhibitor of JAK1, was recently approved in the U.S. as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) and an inadequate response […]

The first listed BTK inhibitor – Imbruvica

The first listed BTK inhibitor – Imbruvica

The sales of 2018 global small molecule drug apixaban replaced lenalidomide with a slight advantage, ranking first, and immediately after the two, it is the Imbruvica, the first listed BTK […]

Overview of Global approval of New drugs in July 2019

Overview of Global approval of New drugs in July 2019

In July 2019, the world’s first approval of new drugs was concentrated in the United States. The FDA (US Food and Drug Administration) approves three new molecular entity drugs (NME), […]

Apixaban

Apixaban

In the past 2018, the global drug sales champion was still the macromolecular monoclonal antibody Humira (just short of $20 billion). The Top2 variety is a small molecular drug, but […]